{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:24:41Z","timestamp":1791404681125,"version":"4.3.3"},"reference-count":153,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FAPESP","award":["2018\/13877-1"],"award-info":[{"award-number":["2018\/13877-1"]}]},{"name":"FAPESP","award":["2015\/17177-6"],"award-info":[{"award-number":["2015\/17177-6"]}]},{"name":"FAPESP","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"FAPESP","award":["2020\/09270-4"],"award-info":[{"award-number":["2020\/09270-4"]}]},{"name":"FAPESP","award":["2020\/06613-8"],"award-info":[{"award-number":["2020\/06613-8"]}]},{"name":"FAPESP","award":["306866\/2020-0"],"award-info":[{"award-number":["306866\/2020-0"]}]},{"name":"FAPESP","award":["308276\/2021-3"],"award-info":[{"award-number":["308276\/2021-3"]}]},{"name":"CAPES","award":["2018\/13877-1"],"award-info":[{"award-number":["2018\/13877-1"]}]},{"name":"CAPES","award":["2015\/17177-6"],"award-info":[{"award-number":["2015\/17177-6"]}]},{"name":"CAPES","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"CAPES","award":["2020\/09270-4"],"award-info":[{"award-number":["2020\/09270-4"]}]},{"name":"CAPES","award":["2020\/06613-8"],"award-info":[{"award-number":["2020\/06613-8"]}]},{"name":"CAPES","award":["306866\/2020-0"],"award-info":[{"award-number":["306866\/2020-0"]}]},{"name":"CAPES","award":["308276\/2021-3"],"award-info":[{"award-number":["308276\/2021-3"]}]},{"name":"fellowships from FAPESP","award":["2018\/13877-1"],"award-info":[{"award-number":["2018\/13877-1"]}]},{"name":"fellowships from FAPESP","award":["2015\/17177-6"],"award-info":[{"award-number":["2015\/17177-6"]}]},{"name":"fellowships from FAPESP","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"fellowships from FAPESP","award":["2020\/09270-4"],"award-info":[{"award-number":["2020\/09270-4"]}]},{"name":"fellowships from FAPESP","award":["2020\/06613-8"],"award-info":[{"award-number":["2020\/06613-8"]}]},{"name":"fellowships from FAPESP","award":["306866\/2020-0"],"award-info":[{"award-number":["306866\/2020-0"]}]},{"name":"fellowships from FAPESP","award":["308276\/2021-3"],"award-info":[{"award-number":["308276\/2021-3"]}]},{"name":"CNPq","award":["2018\/13877-1"],"award-info":[{"award-number":["2018\/13877-1"]}]},{"name":"CNPq","award":["2015\/17177-6"],"award-info":[{"award-number":["2015\/17177-6"]}]},{"name":"CNPq","award":["001"],"award-info":[{"award-number":["001"]}]},{"name":"CNPq","award":["2020\/09270-4"],"award-info":[{"award-number":["2020\/09270-4"]}]},{"name":"CNPq","award":["2020\/06613-8"],"award-info":[{"award-number":["2020\/06613-8"]}]},{"name":"CNPq","award":["306866\/2020-0"],"award-info":[{"award-number":["306866\/2020-0"]}]},{"name":"CNPq","award":["308276\/2021-3"],"award-info":[{"award-number":["308276\/2021-3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Nature is the largest pharmacy in the world. Doxorubicin (DOX) and paclitaxel (PTX) are two examples of natural-product-derived drugs employed as first-line treatment of various cancer types due to their broad mechanisms of action. These drugs are marketed as conventional and nanotechnology-based formulations, which is quite curious since the research and development (R&amp;D) course of nanoformulations are even more expensive and prone to failure than the conventional ones. Nonetheless, nanosystems are cost-effective and represent both novel and safer dosage forms with fewer side effects due to modification of pharmacokinetic properties and tissue targeting. In addition, nanotechnology-based drugs can contribute to dose modulation, reversion of multidrug resistance, and protection from degradation and early clearance; can influence the mechanism of action; and can enable drug administration by alternative routes and co-encapsulation of multiple active agents for combined chemotherapy. In this review, we discuss the contribution of nanotechnology as an enabling technology taking the clinical use of DOX and PTX as examples. We also present other nanoformulations approved for clinical practice containing different anticancer natural-product-derived drugs.<\/jats:p>","DOI":"10.3390\/pharmaceutics14081722","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T22:53:30Z","timestamp":1660776810000},"page":"1722","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4965-1168","authenticated-orcid":false,"given":"Rodrigo dos A.","family":"Miguel","sequence":"first","affiliation":[{"name":"Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-9875","authenticated-orcid":false,"given":"Amanda S.","family":"Hirata","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Institute of the Sea, Federal University of Sao Paulo, Santos 11070-100, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana B.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1861-5153","authenticated-orcid":false,"given":"Leticia V.","family":"Costa-Lotufo","sequence":"additional","affiliation":[{"name":"Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil"},{"name":"Department of Human Biology, University of Cape Town, Cape Town 7925, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1002\/ptr.7099","article-title":"Natural products: A lead for drug discovery and development","volume":"35","author":"Chopra","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_3","first-page":"6","article-title":"DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy","volume":"252","author":"Calil","year":"2021","journal-title":"Cancer Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s11658-019-0164-y","article-title":"Progress in research on paclitaxel and tumor immunotherapy","volume":"24","author":"Zhu","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_5","first-page":"3465","article-title":"Nanopharmacology in translational hematology and oncology","volume":"9","author":"Tomuleasa","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/nnm.13.8","article-title":"Therapeutic nanoparticles in clinics and under clinical evaluation","volume":"8","author":"Mueller","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_7","unstructured":"US Food and Drug Administration (2022, June 11). Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considering-whether-fda-regulated-product-involves-application-nanotechnology."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.2217\/nnm-2020-0290","article-title":"Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline","volume":"15","author":"Hirata","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_9","first-page":"3","article-title":"The discovery of daunorubicin","volume":"65","author":"Cassinelli","year":"1981","journal-title":"Cancer Treat. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bit.260110607","article-title":"Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius","volume":"11","author":"Arcamone","year":"1969","journal-title":"Biotechnol. Bioeng."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J. Am. Chem Soc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1634\/theoncologist.1-4-240","article-title":"The clinical development of paclitaxel: A successful collaboration of academia, industry and the national cancer institute","volume":"1","author":"Donehower","year":"1996","journal-title":"Oncologist"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/bk-1976-0030.ch002","article-title":"Adriamycin","volume":"Volume 30","author":"Henry","year":"1976","journal-title":"Cancer Chemotherapy"},{"key":"ref_14","first-page":"368","article-title":"DNA complexing antibiotics: Daunomycin, adriamycin and their derivatives","volume":"25","author":"Marco","year":"1975","journal-title":"Arzneimittelforschung"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110834","DOI":"10.1016\/j.fct.2019.110834","article-title":"An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients","volume":"134","author":"Battino","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Denard, B., Pavia-Jimenez, A., Chen, W., Williams, N.S., Naina, H., Collins, R., Brugarolas, J., and Ye, J. (2015). Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129233"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"Schiff","year":"1979","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1083\/jcb.91.2.479","article-title":"Taxol binds to polymerized tubulin in vitro","volume":"91","author":"Parness","year":"1981","journal-title":"J. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0165-6147(92)90048-B","article-title":"Mechanism of action of taxol","volume":"13","author":"Horwitz","year":"1992","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"229ra43","DOI":"10.1126\/scitranslmed.3007965","article-title":"Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles","volume":"6","author":"Zasadil","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrclinonc.2010.228","article-title":"Mitosis is not a key target of microtubule agents in patient tumors","volume":"8","author":"Sackett","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14094","DOI":"10.1073\/pnas.93.24.14094","article-title":"BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway","volume":"93","author":"Strobel","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s13273-020-00093-7","article-title":"Paclitaxel inhibits proliferation and promotes apoptosis through regulation ROS and endoplasmic reticulum stress in osteosarcoma cell","volume":"16","author":"Li","year":"2020","journal-title":"Mol. Cell. Toxicol."},{"key":"ref_25","first-page":"8289","article-title":"Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT\/MAPK signaling pathway in canine mammary gland tumor cells","volume":"17","author":"Ren","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gallego-Jara, J., Lozano-Terol, G., Sola-Mart\u00ednez, R.A., C\u00e1novas-D\u00edaz, M., and de Diego Puente, T. (2020). A compressive review about taxol. Molecules, 25.","DOI":"10.3390\/molecules25245986"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel Reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res."},{"key":"ref_28","unstructured":"US Food and Drug Administration (2022, July 27). Doxorubicin Hydrochloride Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050467s073lbl.pdf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","article-title":"Molecular mechanism of doxorubicin-induced cardiomyopathy\u2014An update","volume":"818","author":"Renu","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","unstructured":"US Food and Drug Administration (2022, July 27). Taxol (Paclitaxel Injection) Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020262s049lbl.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CAD.0000000000000063","article-title":"Nature as a remarkable chemist: A personal story of the discovery and development of Taxol","volume":"25","author":"Wani","year":"2014","journal-title":"Anticancer. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","article-title":"Albumin-bound paclitaxel: A next-generation taxane","volume":"7","author":"Gradishar","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2217\/17435889.2.4.415","article-title":"Nanoparticle albumin-bound paclitaxel: A novel Cremphor-EL-free formulation of paclitaxel","volume":"2","author":"Stinchcombe","year":"2007","journal-title":"Nanomedicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101096","DOI":"10.1016\/j.plipres.2021.101096","article-title":"Lipid nanovesicles for biomedical applications: \u2018What is in a name\u2019?","volume":"82","author":"Hauschke","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/380561a0","article-title":"Doxorubicin in sterically stabilized liposomes","volume":"380","author":"Lasic","year":"1996","journal-title":"Nature"},{"key":"ref_39","unstructured":"US Food and Drug Administration (2022, July 27). Doxil Label, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/050718s029lbl.pdf."},{"key":"ref_40","unstructured":"European Medicines Agency (2022, July 27). Caelyx, INN-Doxorubicin Hydrochloride. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/caelyx-pegylated-liposomal-epar-product-information_en.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/0277-5379(89)90350-7","article-title":"Systemic administration of doxorubicin-containing liposomes in cancer patients: A phase I study","volume":"25","author":"Gabizon","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: Nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal formulations in clinical use: An updated review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_45","unstructured":"European Medicines Agency (2022, July 27). Myocet, INN-Doxorubicin. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myocet-liposomal-previously-myocet-epar-product-information_en.pdf."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00273522","article-title":"Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin","volume":"23","author":"Balazsovits","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2174\/1871520617666171121124610","article-title":"Comparison of physicochemical properties of generic doxorubicin HCl liposome injection with the reference listed drug","volume":"18","author":"Maiti","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Burade, V., Bhowmick, S., Maiti, K., Zalawadia, R., Ruan, H., and Thennati, R. (2017). Lipodox\u00ae (generic doxorubicin hydrochloride liposome injection): In vivo efficacy and bioequivalence versus Caelyx\u00ae (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3377-3"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-018-3643-3","article-title":"Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil","volume":"82","author":"Bhowmik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.02.033","article-title":"Equivalency challenge: Evaluation of Lipodox\u00ae as the generic equivalent for Doxil\u00ae in a human ovarian cancer orthotropic mouse model","volume":"141","author":"Smith","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1078155215594415","article-title":"Is it equivalent? Evaluation of the clinical activity of single agent Lipodox\u00ae compared to single agent Doxil\u00ae in ovarian cancer treatment","volume":"22","author":"Smith","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_52","unstructured":"US Food and Drug Administration (2022, July 27). Abraxane (Paclitaxel) Injection, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021660s047lbl.pdf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol"},{"key":"ref_55","unstructured":"European Medicines Agency (2022, July 27). Abraxane. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abraxane."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/annonc\/mdn661","article-title":"Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)","volume":"20","author":"Roy","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial","volume":"17","author":"Untch","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10549-016-3736-9","article-title":"Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: A multicenter, randomized, comparative phase II\/III study","volume":"156","author":"Jain","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Yadav, H.K., Almokdad, A.A., Sumia, I., and Debe, M.S. (2019). Polymer-based nanomaterials for drug-delivery carriers. Nanocarriers for Drug Delivery, Elsevier.","DOI":"10.1016\/B978-0-12-814033-8.00017-5"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4155\/tde-2020-0008","article-title":"Polymeric micelles for anticancer drug delivery","volume":"11","author":"Majumder","year":"2020","journal-title":"Ther. Deliv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12094-012-0883-2","article-title":"Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM)","volume":"15","author":"Madaan","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0168-3659(01)00275-9","article-title":"In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy","volume":"72","author":"Kim","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"Ahn","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/annonc\/mdm374","article-title":"Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Kim","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","article-title":"Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies","volume":"10","author":"Kim","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-5173(95)04386-1","article-title":"Development of amphiphilic diblock copolymers as micellar carriers of taxol","volume":"132","author":"Zhang","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_70","unstructured":"European Medicines Agency (2022, June 11). Apealea, INN-Paclitaxel. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/apealea-epar-product-information_en.pdf."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1007\/s12325-019-00909-6","article-title":"Maximum tolerated dose and pharmacokinetics of paclitaxel micellar in patients with recurrent malignant solid tumours: A dose-escalation study","volume":"36","author":"Henriksson","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2017.09.026","article-title":"Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy","volume":"267","author":"Wang","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/aps.2016.105","article-title":"Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase","volume":"38","author":"Jang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jddst.2018.09.014","article-title":"Effect of paclitaxel content in the DHP107 oral formulation on oral bioavailability and antitumor activity","volume":"48","author":"Jang","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eurpolymj.2005.09.027","article-title":"The synthesis, characterisation, phase behaviour and swelling of temperature sensitive physically crosslinked poly (1-vinyl-2-pyrrolidinone)\/poly (N-isopropylacrylamide) hydrogels","volume":"42","author":"Geever","year":"2006","journal-title":"Eur. Polym. J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"601626","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2013.08.079","article-title":"Nanocarriers for intravenous injection\u2014The long hard road to the market","volume":"457","author":"Wacker","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001813-200606000-00014","article-title":"Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis","volume":"17","author":"Batist","year":"2006","journal-title":"Anticancer Drugs"},{"key":"ref_83","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_84","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts","volume":"44","author":"Thuerlimann","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Neun, B.W., Barenholz, Y., Szebeni, J., and Dobrovolskaia, M.A. (2018). Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro. Molecules, 23.","DOI":"10.3390\/molecules23071700"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2019.06.007","article-title":"Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs","volume":"306","author":"Bavli","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3816\/CLM.2008.n.001","article-title":"Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal Doxorubicin","volume":"8","author":"Soloman","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0304-4165(78)90025-9","article-title":"Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins","volume":"542","author":"Scherphof","year":"1978","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0014-5793(80)80819-2","article-title":"Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum","volume":"111","author":"Kirby","year":"1980","journal-title":"FEBS Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00001813-200303000-00008","article-title":"Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer","volume":"14","author":"Swenson","year":"2003","journal-title":"Anticancer Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jnci\/90.4.300","article-title":"Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study","volume":"90","author":"Szebeni","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_97","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jconrel.2012.09.006","article-title":"Liposomal paclitaxel formulations","volume":"163","author":"Koudelka","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijrobp.2013.02.009","article-title":"Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer","volume":"86","author":"Werner","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_100","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jemt.10086","article-title":"Transcytosis of plasma macromolecules in endothelial cells: A cell biological survey","volume":"57","author":"Simionescu","year":"2002","journal-title":"Microsc. Res. Tech."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"L187","DOI":"10.1152\/ajplung.00152.2002","article-title":"Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer","volume":"284","author":"John","year":"2003","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1535-7163.MCT-07-0261","article-title":"Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation","volume":"6","author":"Hong","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1345\/aph.19347","article-title":"Clinical pharmacology of encapsulated sustained-release cytarabine","volume":"34","author":"Murry","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.nano.2015.06.007","article-title":"In vitro experiments showing enhanced release of doxorubicin from Doxil\u00ae in the presence of ammonia may explain drug release at tumor site","volume":"11","author":"Silverman","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2013.08.034","article-title":"Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: Evaluated by in vitro\/in vivo live cell imaging","volume":"172","author":"Seynhaeve","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10555-008-9135-x","article-title":"The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host","volume":"27","author":"Podhajcer","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/00004424-200204000-00004","article-title":"Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: Use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity","volume":"37","author":"Kiessling","year":"2002","journal-title":"Investig. Radiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1158\/0008-5472.CAN-17-0604","article-title":"Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy","volume":"77","author":"Chatterjee","year":"2017","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5732\/cjc.011.10326","article-title":"Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology","volume":"31","author":"Xue","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/mp2001389","article-title":"Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells","volume":"8","author":"Riganti","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/03639045.2015.1054396","article-title":"P-glycoprotein inhibition of drug resistant cell lines by nanoparticles","volume":"42","author":"Singh","year":"2016","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/0008-5472.CAN-08-2747","article-title":"Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP","volume":"69","author":"Dong","year":"2009","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/17425255.2016.1196186","article-title":"Nano-based strategies to overcome p-glycoprotein-mediated drug resistance","volume":"12","author":"Niazi","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2147\/IJN.S129976","article-title":"Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1\/GNA1)","volume":"12","author":"Zhao","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","article-title":"Albumin nanoparticle of paclitaxel (abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer","volume":"17","author":"Yuan","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.electacta.2018.12.164","article-title":"Voltammetric and biological studies of folate-targeted non-lamellar lipid mesophases","volume":"299","author":"Godlewska","year":"2019","journal-title":"Electrochim. Acta"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e10143","DOI":"10.1002\/btm2.10143","article-title":"Nanoparticles in the clinic: An update","volume":"4","author":"Anselmo","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/17425247.2013.758631","article-title":"Hyperthermia-induced drug targeting","volume":"10","author":"May","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","volume":"93","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e10246","DOI":"10.1002\/btm2.10246","article-title":"Nanoparticles in the clinic: An update post COVID-19 vaccines","volume":"6","author":"Anselmo","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"120355","DOI":"10.1016\/j.biomaterials.2020.120355","article-title":"Lactoferrin, a multi-functional glycoprotein: Active therapeutic, drug nanocarrier & targeting ligand","volume":"263","author":"Elzoghby","year":"2020","journal-title":"Biomaterials"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"32062","DOI":"10.1038\/srep32062","article-title":"Doxorubicin conjugated to immunomodulatory anticancer lactoferrin displays improved cytotoxicity overcoming prostate cancer chemo resistance and inhibits tumour development in TRAMP mice","volume":"6","author":"Shankaranarayanan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1021\/mp400189j","article-title":"Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy","volume":"11","author":"Miao","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_127","first-page":"295","article-title":"Nanocrystal technology, drug delivery and clinical applications","volume":"3","author":"Junghanns","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0043-119461","article-title":"Evaluation of paclitaxel nanocrystals in vitro and in vivo","volume":"68","author":"Li","year":"2018","journal-title":"Drug Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08982104.2019.1682604","article-title":"Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin","volume":"31","author":"Sesarman","year":"2021","journal-title":"J. Liposome Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.xphs.2017.09.007","article-title":"Evidence that P-glycoprotein inhibitor (Elacridar)-loaded nanocarriers improve epidermal targeting of an anticancer drug via absorptive cutaneous transporters inhibition","volume":"107","author":"Giacone","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejps.2017.07.023","article-title":"Co-encapsulation of paclitaxel and C6 ceramide in tributyrin-containing nanocarriers improve co-localization in the skin and potentiate cytotoxic effects in 2D and 3D models","volume":"109","author":"Carvalho","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-018-1022-3","article-title":"Daunorubicin\/cytarabine liposome: A review in acute myeloid Leukaemia","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_133","unstructured":"(2022, June 11). Drugs.com. Prices, Coupons & Patient Assistance Programs. Available online: https:\/\/www.drugs.com\/price-guide\/."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.2147\/IJN.S323831","article-title":"Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment","volume":"16","author":"Milewska","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1053\/j.seminoncol.2004.08.008","article-title":"Pharmacoeconomics of liposomal anthracycline therapy","volume":"31","author":"Bennett","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/erp.13.18","article-title":"Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain","volume":"13","author":"Alba","year":"2013","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","first-page":"635","article-title":"FDA advisors okay NeXstar\u2019s DaunoXome","volume":"13","author":"Fox","year":"1995","journal-title":"Bio\/Technology"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(00)00292-8","article-title":"Marine organisms as a source of new anticancer agents","volume":"2","author":"Schwartsmann","year":"2001","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/104345429000700406","article-title":"Cytarabine","volume":"7","author":"Betcher","year":"1990","journal-title":"J. Pediatr. Oncol. Nurs."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamurtide for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"Ando","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioeng Transl Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(98)00023-7","article-title":"Vincristine revisited","volume":"29","author":"Gidding","year":"1999","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/fon.15.333","article-title":"MM-398 (nanoliposomal irinotecan): Emergence of a novel therapy for the treatment of advanced pancreatic cancer","volume":"12","author":"Carnevale","year":"2016","journal-title":"Future Oncol."},{"key":"ref_146","first-page":"212","article-title":"Abrindo a caixa de pandora dos nanomedicamentos: H\u00e1 realmente muito mais \u2018espa\u00e7o l\u00e1 embaixo\u2019","volume":"43","author":"Salata","year":"2020","journal-title":"Qu\u00edmica Nova"},{"key":"ref_147","unstructured":"European Medicines Agency (2022, July 27). Nanotechnology. Available online: https:\/\/www.ema.europa.eu\/en\/glossary\/nanotechnology."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jin2.34","article-title":"Identification of regulatory needs for nanomedicines","volume":"3","author":"Borgos","year":"2018","journal-title":"J. Interdiscip. Nanomed."},{"key":"ref_149","unstructured":"US Food and Drug Administration (2022, July 27). Drug Products, Including Biological Products, That Contain Nanomaterials, Available online: https:\/\/www.fda.gov\/media\/157812\/download."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.11.021","article-title":"An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil\u00ae, Caelyx\u00ae, DOXOrubicin, and SinaDoxosome","volume":"221","author":"Wibroe","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Zhao, M., Lei, C., Yang, Y., Bu, X., Ma, H., Gong, H., Liu, J., Fang, X., Hu, Z., and Fang, Q. (2015). Abraxane, the nanoparticle formulation of paclitaxel can induce drug resistance by up-regulation of P-gp. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0131429"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: Evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"120910","DOI":"10.1016\/j.biomaterials.2021.120910","article-title":"Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation","volume":"275","author":"Luan","year":"2021","journal-title":"Biomaterials"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/8\/1722\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:22Z","timestamp":1760141482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/8\/1722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":153,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["pharmaceutics14081722"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14081722","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,17]]}}}